NY, London and San Fran: Come see me on FierceBiotech's mini-global October tour

We're coming down to the wire for FierceBiotech's half-day executive conference in London next Monday, October 12, where I'll be moderating discussions on biotech financing, the IPO market (that should be interesting) and clinical trial design in an age of widespread collaborations between biotechs and Big Pharma.

You can check out the full program and register here. Among the many panelists you'll find Tim Haines at Abingworth, Rafaèle Tordjman from Sofinnova, Sam Fazeli at Bloomberg Intelligence and Mene Pangalos, the head of early-stage development at AstraZeneca ($AZN). Plus, many more pros in the U.K. biotech hub.

October in general will be a busy travel month here at FierceBiotech. I'll be in New York tomorrow evening, moderating a panel discussion on biotech innovation with some very interesting people in the industry. A Harvard alumni club put together the panel and the agenda, allowing this non-Harvard grad to participate. 

After London I'm headed to San Francisco for a Fierce 15 panel and reception at the BIO Investor Forum.

We've just published the 13th annual Fierce 15 for FierceBiotech, and some of the winners from past and present will join me to discuss some of the particular issues revolving around gaining recognition as a cutting-edge drug developer in 2015. I'll be particularly keen to see if the new class of biotechs can equal the extraordinary success of last year's Fierce 15 on the public market. 

They set a very high bar, with 8 IPOs and two more waiting in the wings.

Hopefully you'll find a chance to meet with me somewhere along the way of the mini-global tour. If you have any questions, drop me a line. John Carroll, editor-in-chief (email | Twitter)

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.